Alexion Pharmaceuticals (NASDAQ:ALXN) EVP John J. Orloff sold 2,115 shares of the stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $118.53, for a total transaction of $250,690.95. Following the transaction, the executive vice president now owns 31,790 shares in the company, valued at $3,768,068.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ ALXN opened at $118.20 on Thursday. The firm has a market capitalization of $25.97 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 1.05 and a beta of 1.11. Alexion Pharmaceuticals has a 12-month low of $102.10 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.18. The business had revenue of $930.90 million during the quarter, compared to analysts’ expectations of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $1.38 earnings per share. equities analysts anticipate that Alexion Pharmaceuticals will post 6.28 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Delpha Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth $102,000. Point72 Asia Hong Kong Ltd raised its holdings in shares of Alexion Pharmaceuticals by 3,156.7% in the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 947 shares during the last quarter. CNB Bank purchased a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth $150,000. Lucia Wealth Services LLC purchased a new position in shares of Alexion Pharmaceuticals in the first quarter worth $191,000. Finally, Financial Gravity Wealth Inc. purchased a new position in shares of Alexion Pharmaceuticals in the first quarter worth $211,000. 92.26% of the stock is owned by institutional investors and hedge funds.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.